Vertex Pharmaceuticals (VRTX) Q2 2026 Earnings
As seen on the 24/7 Wall St. homepage on August 3, 2026.
Q2 2026
EPS
$4.73
est $4.75
-0.3%
Revenue
$3.33B
est $3.22B
+3.4%
Vertex lifted full-year revenue guidance to $13.1 billion to $13.2 billion, with management now committing to at least $500 million from non-CF products this year. That guidance excludes the pending $10 billion Crinetics deal, so the next update comes after the deal closes in Q3.
Mentioned: VRTX